European pharmaceutical company offers its investigational medicinal product to a wide range of specialist medical practitioners in the United Kingdom
Epidiolex's Success Highlights Potential for MGC Pharma's CannEpil®
The recent success of Epidiolex, a CBD-based epilepsy treatment that generated $296 million in sales in 2019, highlights the potential for MGC Pharma's CannEpil® in the UK market. This underlines the potential of CannEpil®, an investigational medicinal product for patients suffering from refractory epilepsy, to make a significant impact in the UK market.
LONDON, April 11, 2023 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based pharmaceutical company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.
MGC Pharma's CannEpil® is an investigational medicinal product (IMP) designed for patients suffering from refractory epilepsy, also known as drug-resistant epilepsy. The high-CBD, low-THC formulation is administered via an oral mucosal solution and is currently undergoing a clinical development program. The availability of CannEpil® in the UK follows the company's announcement that it is providing the product for an observational trial supported by the I am Billy Foundation.
With this development, clinicians in the UK listed on the General Medical Council (GMC) Specialist Register can now prescribe CannEpil®. This is a significant milestone for MGC Pharma and patients with unmet medical needs, as it expands the company's reach within the healthcare and life science sectors as an innovative plant-inspired pharmaceutical company.
CannEpil® has already been prescribed to hundreds of patients across Australia and the Republic of Ireland over the past three years. In 2019, it became the first product to be available with coverage in the Republic of Ireland under the Long Term Illness and General Medical Services schemes.
The data collected from patients using CannEpil® will be used to further evaluate the safety and efficacy of the drug, supporting future submissions for marketing authorization.
Epilepsy affects approximately 50 million people worldwide, with 33% of adults and 20-25% of children suffering from refractory epilepsy. CBD has been proven effective in reducing seizure frequency and severity, as supported by open-label studies, observational studies, randomized clinical trials (RCTs), and large-scale systematic reviews.
Roby Zomer, Managing Director and CEO of MGC Pharmaceuticals, commented: "The availability of CannEpil® by Named Patient Request marks a momentous breakthrough for MGC Pharma. The product will now be available to a wide cohort of specialist medical practitioners in the UK, which is testament to the progress we are making."
"We are extremely proud of the progress we have achieved thus far, and we are pleased that CannEpil® has been selected as a treatment within an observational patient trial in association with the I am Billy Foundation. We look forward to updating the market on the results of this trial in due course."
HTTP://MGCpharma.eu
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
Logo - https://mma.prnewswire.com/media/1780050/mgcpharma_logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/mgc-pharmas-cannepil-now-accessible-to-uk-patients-on-named-patient-request-basis-301793534.html
